statins and congenital malformations
DESCRIPTION
PresentationTRANSCRIPT
![Page 1: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/1.jpg)
Scott Yee
![Page 2: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/2.jpg)
Introduction
• Statins are the most commonly used class of drug used to treat hyperlipidemia
• Considered contraindicated in pregnancy based on animal studies.
• FDA data on effects in utero exposure on fetal development in humans are few.
• Important to understand statin’s effects in utero:• ½ of all pregnancies in US are unintended• Preclinical studies suggest statins can prevent Pre-
eclampsia.
![Page 3: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/3.jpg)
Introduction
• Statins are HMG-CoA Reductase inhibitors • Inhibit conversion of
HMG-CoA to Mevalonate
• Lipophilic medication
• Category X drug due to animal studies
![Page 4: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/4.jpg)
Cohort Inclusions
• Drawn from Medicaid Analytic eXtract
• Data from 46 States and District of Columbia from 2000-2007.
• Women ages 12-55 years old with completed pregnancies that were linked to live born infants.
• Woman that were continuously eligible for Medicaid from three months before the estimated last menstrual period month through one month post partum
![Page 5: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/5.jpg)
Cohort Exclusions
• Pregnancies the mother used known teratogenic drugs• Lithium, antineoplastic, retinoids, thalidomide
• Pregnancies in which the infant was diagnosed with chromosomal abnormalities.
![Page 6: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/6.jpg)
Statins
• Claims based on one or more claims for a dispensed statin from LMP through 90 of pregnancy.
• Simavastatin, Lovastatin, Pravastatin, Fluvastatin, Atorvastin, Cerviastatin, Rosuvastatin
![Page 7: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/7.jpg)
Measured Outcomes
• Presence of Congenital malformations• Diagnosis of one or more organ specific
malformations• CNS, eye, ear, face, cardiac, respiratory, cleft
palate or lip, GI, GU, musculoskeletal.• Presence of international classification of
diseases on two or more separate days in the infant inpatient or outpatient records during first three months of life.
![Page 8: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/8.jpg)
Covariates
• Maternal Demographics• Age at delivery, race, geographic region, year of delivery
• Comorbid Medical Conditions • Baseline period (Last menstrual period through the end of the 1st
trimester)• Pre-existing diabetes, dyslipidemia, pre-existing HTN, chronic renal
disease, obesity and ETOH, tobacco, or illicit drug
• Obstetric Characters • Multiparity and multiple gestations
• Drugs dispense to mother (other than statins)• 3 moths before LMP • Baseline period • Drug prescriptions and physician visits
![Page 9: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/9.jpg)
Covariates
![Page 10: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/10.jpg)
Statistical Analysis
• Estimated association between statin use and primary outcome stratified on pre-existing DM with Mantel Haenszel method.
• Propensity score used to measure differences in baseline characteristics of women who did and didn't’t not use statins • Logistic regression model that estimated the
probability of being dispensed a statin in the 1st trimester based on potential variables.
![Page 11: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/11.jpg)
Subgroup and Sensitivity analyses
![Page 12: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/12.jpg)
Subgroup and Sensitivity analyses
• Two alternative definitions of first trimester statin use:• Days supply of statin overlapping 1st trimester
based on dispensing 90 days prior to the LMP through the end of the 1st trimester
• Two or more statin dispensing during the 1st trimester
![Page 13: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/13.jpg)
Results
• Primary cohort 886,996 pregnancies
• 1152 women filled a prescription for statin drugs during the first trimester.
![Page 14: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/14.jpg)
![Page 15: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/15.jpg)
Risk and Relative Risk
![Page 16: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/16.jpg)
Malformations
![Page 17: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/17.jpg)
Sensitivity and Subgroups
![Page 18: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/18.jpg)
Discussion
• Found no significant association between maternal Use of statins in the first trimester and risk for congenital malformations
• The importance of this finding is 2 fold:1. Increase amount of women in reproductive
age that need statins
2. Potential for statins to aid in the treatment of pre-eclampsia
![Page 19: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/19.jpg)
Discussion
• Weakness• Assumption that a statin is dispensed it is
taken. However, this cannot be verified. • Cannot exclude the possibility that statins
have long term affects.
![Page 20: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/20.jpg)
Question
• Which of the following is NOT a reason for Statin’s presumed association with fetal malformations?
A. The lipophilic nature of some statins
B. Animal Models showed tetratagenic effects
C. Data from the FDA shows tetragenic effects
D. Statins causes defects in astrocyte migration
![Page 21: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/21.jpg)
Question
• Which of the following can be a benefit with statin use in a pregnant women?
A. Statins maybe beneficial for fetuses that have hyperlipidemia
B. Statins maybe beneficial for pregnant women that have pre-eclampsia
C. Statins have been shown to decrease miscarriage rates.
D. Statins have no benefits to the mother or child
![Page 22: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/22.jpg)
Question
• Which of the following is NOT a known teratogenic drug during the first trimester?
A. Lithium
B. Retinoids
C. Insulin
D. Thalidomid
![Page 23: Statins and Congenital Malformations](https://reader035.vdocuments.site/reader035/viewer/2022062423/563dbad9550346aa9aa89026/html5/thumbnails/23.jpg)
Bibliography
• BMJ 2015;350:h1035 doi: 10.1136/bmj.h1035
• Rosenson, RS. Statins: Actions, side effects, and administration. In: UpToDate, Post, TW (Ed), UpToDate, Waltham, MA, 2014.